New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
08:36 EDTMRK, BIIB, SSNLFMerck, Samsung Bioepis enter collaboration agreement
Merck (MRK) and Samsung Bioepis, a joint venture between Samsung (SSNLF) Biologics and Biogen (BIIB), announced that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon. Under the terms of the agreement, the companies will collaborate on clinical development, regulatory filings and manufacturing. If approved, Merck will commercialize this candidate. This collaboration builds on the agreement made by the two companies in February 2013 to develop and commercialize multiple biosimilar candidates.
News For MRK;SSNLF;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 22, 2015
07:19 EDTBIIBBiogen drops 4.8% to $390 after reporting Alzheimer's drug data
07:04 EDTMRKMerck's Keytruda approved by EU for treatment of advanced melanoma in adults
Merck announced that the European Commission has approved KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of advanced melanoma in adults. The European Commission approval of pembrolizumab is based on data from three clinical studies conducted in more than 1,500 first-line and previously-treated patients with advanced melanoma. Pembrolizumab received European Commission regulatory approval based on Phase 3 data which showed it is the first and only anti-PD-1 therapy to provide a statistically superior survival benefit as a monotherapy compared to ipilimumab, the current standard of care for advanced melanoma. Today’s approval allows marketing of pembrolizumab in all 28 EU member states at the approved dose of 2 mg/kg every three weeks. The European Commission’s approval is based on data from three studies -- KEYNOTE-001, KEYNOTE-002 and KEYNOTE-006. These studies evaluated the efficacy and safety of pembrolizumab in advanced melanoma patients – across treatment lines, prognostic factors, tumor characteristics, and BRAF mutational status – and established 2 mg/kg every three weeks as the approved dose.
06:50 EDTBIIBBiogen's Alzheimer's candidate shows reduction of clinical decline
Subscribe for More Information
06:05 EDTMRKMerck, Ablynx expand immuno-oncology collaboration
Subscribe for More Information
05:55 EDTSSNLFDRAMeXchange: DRAM prices to fall further, DigiTimes says
Subscribe for More Information
July 21, 2015
06:24 EDTBIIBPiper expects 'stronger, bolder' move from Biogen
Subscribe for More Information
06:19 EDTSSNLFSilicon Valley giants side with Samsung in battle with Apple, InsideSources says
Subscribe for More Information
06:12 EDTBIIBBiogen implied volatility of 50 at upper end of index
July 20, 2015
13:28 EDTSSNLFSamsung most popular smartphone maker in Q2, TrendForce says
Samsung (SSNLF) was the most popular smartphone maker in the second quarter, even though the smartphone market has started to slow down, according to data from research firm TrendForce. Smartphone shipments will grow 8.2% year over year in 2015, though that's down from the previously anticipated growth rate of 11.6%, the report says. Samsung has led in smartphone shipments with a second-quarter growth of 26.8%. However, Galaxy S6 and S6 Edge's annual shipment forecast has been marked down repeatedly. TrendForce has also revised Samsung's annual smartphone shipments downwards to 45M units this year. As Chinese vendors are taking more shares of the low- to mid-range product market, Samsung's ability to reverse its fortune may hinge on the success of its Galaxy Note 5. If this device is able to attract consumers with upgraded specs and new features, then Samsung will avoid the high possibility of negative shipment growth for this year. Apple (AAPL) rode on the popularity of iPhone 6 and iPhone 6 Plus in this year's first half and achieved a remarkably strong shipment result in the off-peak season. The next-generation iPhone due to be launched this year offers no major changes in appearance, but Apple has given the device a new A9 processor and upgraded its memory to 2GB LPDDR4 for the first time. These improvements along with the Force Touch module and a camera featuring a possible resolution of 12MP will give the next iPhone a huge boost. Thus, TrendForce's iPhone shipment forecast for this year continues to be very positive with a high growth of 15% upwards. Lenovo (LNVGY) has fallen to No. 6 in the global shipment ranking and is expected to see a 20%-30% decline in this year's shipments. Lenovo's market share did not double as anticipated after its takeover of Motorola in 2014. Moreover, Lenovo did not have a well-defined product positioning strategy and the brand faced strong competition from challengers offering lower-priced smartphone models.
07:32 EDTBIIBAlzheimer's Association to hold a conference
Subscribe for More Information
July 19, 2015
14:09 EDTSSNLFIntel chip delay could spell opportunity or disaster, Barron's says
Subscribe for More Information
July 17, 2015
05:47 EDTSSNLFSamsung C&T shareholders approve merger with Cheil Industries
Subscribe for More Information
July 16, 2015
18:26 EDTSSNLFXiaomi VP says 'absolutely' coming to U.S., Bloomberg TV says
Subscribe for More Information
13:43 EDTSSNLFSemi equipment stocks overreacting to Intel capex cut, says Summit Research
Summit Research said Intel (INTC) is pushing out its 10nm plans for multiple reasons and that TSMC (TSM) and Samsung (SSNLF) will not let a "once in a lifetime opportunity" pass and will speed up their own spending. The firm believes the pullback in semiconductor equipment stocks, particularly Applied Materials (AMAT), KLA-Tencor (KLAC) and Lam Research (LRCX), on Intel's capex guidance cut is somewhat of an overreaction and recommends buying amid the weakness.
13:39 EDTSSNLFSamsung begins rollout of payment service in Korea, TechCrunch reports
Subscribe for More Information
11:53 EDTSSNLFApple and Samsung in talks to launch e-sim card, Financial Times reports
Apple (AAPL) and Samsung (SSNLF) are in advanced talks to launch electronic sim cards, reports the Financial Times. The GSMA is close to announcing an agreement to produce an standardized embedded sim for consumer devices that would include the smartphone makers. Reference Link
06:32 EDTSSNLFSamsung tries home visits to woo investors to approve Cheil, C&T deal, WSJ says
Subscribe for More Information
06:14 EDTSSNLFMetLife Insurance to vote Samsung C&T shares in favor of Cheil, Reuters says
Subscribe for More Information
05:46 EDTSSNLFTSMC and Samsung begin A9 chip mass production, DigiTimes reports
Subscribe for More Information
July 15, 2015
07:58 EDTBIIBAnalysts break down impact of $7.2B Receptos buyout
After Celgene (CELG) announced last night that the company has agreed to acquire Receptos (RCPT) for $232 per share in cash, or a total of about $7.2B net of cash acquired, research firms have chimed in with their opinions on how the proposed deal may impact others in the biotech space. Receptos key asset is Ozanimod, which is being studied in Phase III trials for relapsing multiple sclerosis and ulcerative colitis. DERIVATIVE CALLS: Piper Jaffray analyst Edward Tenthoff told investors that he views Celgene's deal for Receptos as good for Arena Pharmaceuticals (ARNA). The analyst notes that Arena's APD334 is already showing dose-dependent decreases in circulating lymphocyte counts and that the company will initiate Phase II studies in ulcerative colitis and Crohn's disease this year. Tenthoff reiterates an Overweight rating and $7.50 price target on Arena, which has a market capitalization around $1B and closed yesterday up 8c to $4.47. In its own note to investors this morning, Nomura said Celgene's deal could put downward pressure on Biogen's (BIIB) long-term multiple sclerosis estimates. Nomura's M. Ian Somaiya contended that one-year Phase II efficacy data for Ozanimod looked as good as Novartis’s (NVS) Gilenya and Biogen's Tecfidera’s Phase III at year 2. Somaiya also wondered if rival Gilead (GILD) could be "looking for something bigger" than Receptos for its own deal, telling investors that the firm views Incyte (INCY) as Gilead's most likely takeout target. Incyte's shares closed up $4.46 at $117.46 yesterday, giving the company a market cap of about $20B. RIVAL BID?: Wedbush analyst Liana Moussatos believes another bidder may seek to acquire Receptos, noting that she previously estimated Receptos could be valued at $348 per share, or about $10.9B, in a buyout. Moussatos noted that Celgene said it expects annual peak sales for Ozanimod to reach about $4B-$6B for RMS and UC, making its acquisition price of $7.2BN only a bit more than about 1X peak sales without accounting for other possible indications or the rest of its pipeline. Moussatos told investors she sees "plenty" of potential upside to justify a rival bidder stepping in and reiterated the firm's Outperform rating on Receptos shares. PRICE ACTION: In pre-market trading, Receptos rose 10% to $228.61 while Gilead gained 1.4% to about $119 per share.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use